Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    COX-2–selective inhibitors in the treatment of arthritis
    Thomas J. Schnitzer, MD, PhD and Marc C. Hochberg, MD, MPH
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-20-SI-30;
  • You have access
    Epidemiology of Vasculitis
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-165-SII-171;
  • You have access
    Measuring disease activity and outcomes in clinical studies
    Raashid Luqmani, DM, FRCP (Edin)
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-100-SII-102;
  • You have access
    Diagnostic strategies in vasculitis affecting the central nervous system
    Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-105-SII-108;
  • A practical guide for examining and treating the diabetic foot
    You have access
    A practical guide for examining and treating the diabetic foot
    Allan M. Boike, DPM and James O. Hall, DPM
    Cleveland Clinic Journal of Medicine April 2002, 69 (4) 342-348;

    Some tips on performing a quick, focused examination of the diabetic foot for problems in circulation, nerve function, skin, muscles, and bones.

  • You have access
    Chemokine Receptor Expression on CD4+ and CD8+ Memory T-Cells and in Granulomas in Wegener’s Granulomatosis
    P Lamprecht, A Erdmann, A Mueller, E Csernok, H Bruehl, WL Gross and M Mack
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-44;
  • You have access
    BNP looks like a winner
    John D. Clough, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 179;

    Natriuretic peptides are out of the research laboratory and into the clinic and hospital ward.

  • A 52-year-old man with excessive daytime sleepiness
    You have access
    A 52-year-old man with excessive daytime sleepiness
    Bipin D. Sarodia, MD, Reena Mehra, MD and Joseph A. Golish, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 193-207;

    What is the cause of this patient’s symptoms? A self-test.

  • You have access
    What is the best way to determine if thrombocytopenia in a patient on multiple medications is drug-induced?
    Navneet S. Majhail, MD and Alan E. Lichtin, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 259-262;

    The only way is to stop the suspected drug and see if the thrombocytopenia resolves. But how to avoid stopping needed drugs that are not a problem?

  • You have access
    How to use nesiritide in treating decompensated heart failure
    Roger M. Mills, MD and Robert E. Hobbs, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 252-256;

    Nesiritide, a recombinant formulation of BNP, is the first new parenteral drug in more than a decade to be approved for treating heart failure.

Pages

  • Previous
  • Next
  • 1
  • …
  • 391
  • 392
  • 393
  • 394
  • 395
  • 396
  • 397
  • 398
  • 399
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire